Drugs / ORE001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05923086 | Jan 2024 → Dec 2025 overdue | ileus | Orexa BV | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ORE001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05923086 ↗ |
| Route | Oral | “all patients will receive the oral study drug” NCT05923086 ↗ |